vimarsana.com

Page 2 - லக்சை வாழ்க்கை அறிவியல் பிரைவேட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CSIR India and Laxai Life Sciences initiate clinical trials of promising repurposed drug Niclosamide for treatment of Covid-19

New Delhi: CSIR in collaboration with Laxai Life Sciences Pvt. Ltd., has initiated Phase-II clinical trial with anti-helminitic drug Niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomized, open label clinical study

Jammu and kashmirAndhra pradeshNew delhiCity ofUnited kingdomSrivari chandrashekharRam vishwakarmaRam upadhayayaShekharc mandeLaxai life sciences pvtLaxai life sciencesKing collegeDirector generalActive pharmaceutical ingredientஜம்மு மற்றும் காஷ்மீர்ஆந்திரா பிரதேஷ்

Niclosamide used for treating tapeworm infection proven effective against COVID; trials underway

Being held at different sites, phase-II clinical trial of Niclosamide beings for treating COVID will be completed within 8-12 weeks.

Jammu and kashmirCity ofUnited kingdomShekharc mandeNational centre for biological scienceLaxai life sciences pvtCouncil of scientificIndian institute of integrative researchKing collegeIndustrial researchIndustrial research indian instituteIntegrative researchLaxai life sciencesNational centreBiological scienceDirector general

vimarsana © 2020. All Rights Reserved.